In short
Clinical trials investigating GRISNILIMAB SETARITOX are studying its use in early diffuse cutaneous systemic sclerosis, a serious form of autoimmune disease that affects the skin and sometimes internal organs. The trial data focus on safety in a small group of patients and measure harmful events during and after treatment.
Key points
- Clinical trials investigating GRISNILIMAB SETARITOX are focused on early diffuse cutaneous systemic sclerosis, a serious autoimmune disease. The available trial is a Phase 1 interventional study with 13 participants. Its main purpose is to assess safety, especially Grade 3 or higher adverse events. The study follows patients from the first infusion until 28 days after the last administration. The trial is authorised and uses a standard system called CTCAE v5 to grade side effects.
Trial overview
The available study for GRISNILIMAB SETARITOX is an interventional trial in early diffuse cutaneous systemic sclerosis (dcSSc).1 The trial is authorised and includes 13 participants.1
The study title is T-Guard in dcSSc, and the intervention is listed as T-Guard given by intravenous infusion.1
Who is being studied
This trial is focused on people with early dcSSc, which is a form of systemic sclerosis that mainly affects the skin and can also involve other organs.1 The source data do not list broader age groups, sex groups, or other eligibility details.1
Because the study is small, it is designed to give an early look at safety in a limited group of patients rather than to answer all questions about long-term benefit.1
Trial design and phase
This is a Phase 1 study, which means it is an early clinical trial stage that usually focuses on safety first.1 It is also described as an interventional study, meaning participants receive the study treatment and researchers observe what happens.1
The treatment is given by intravenous infusion, which means it is delivered through a vein.1
What the study measures
The main endpoint is the incidence of Grade 3 or higher adverse events using CTCAE v5.1 An adverse event is any medical problem that happens during the study, and Grade 3 or higher means a serious level on the trial safety scale.1
The safety window starts with the first infusion and continues until 28 days after the last T-Guard administration.1 This helps researchers see whether serious problems happen during treatment or shortly after it ends.1
What this means for patients
For patients, this trial is mainly about learning whether the study treatment can be given safely in early dcSSc.1 The study does not provide full proof of benefit, because the source data only describe a safety goal in a small Phase 1 group.1
Since the trial is authorised and already enrolled 13 participants, it shows active clinical research in a specific patient group with a clear safety focus.1